

## **Optimizing Outcomes for Patients with Urothelial Carcinoma**

**November 14, 2020**

**8:00 am – 12:00 pm CT**

**Live Webinar**

**This educational activity is jointly provided by AXIS Medical Education and the Association of Community Cancer Centers (ACCC).**

**This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, Astellas and Seattle Genetics, Inc.**

**Target audience:** The target audience for this initiative includes medical oncologists, urologic oncologists, urologists, advanced practice providers (nurse practitioners, physician assistants, oncology pharmacists), oncology nurses, and other healthcare professionals (HCPs) involved in treating patients with urothelial carcinoma.

**Overview:** Bladder cancer is the most common malignancy in the urinary system. Urothelial carcinoma accounts for 90% of bladder cancers. With the evolving treatment landscape for urothelial carcinoma, community clinicians are challenged to keep abreast with evidence-based practice guidelines, the clinical efficacy for new therapies, monitoring and managing adverse events, and engaging patients sufficiently to help them make informed treatment decisions.

Since community oncologists treat many types of cancers, it is hard for them to gain requisite experience across all tumor types and keep abreast of the evidence-based guidelines for all the cancers. In a recent survey of community cancer care professionals conducted by the Association of Community Cancer Centers (ACCC) in 2018, bladder cancer was reported to be one of the most commonly diagnosed cancers at their cancer center/hospital, after the top 4 most commonly diagnosed cancers in the country, breast, lung, prostate and colorectal cancer. Several knowledge, competence and performance gaps exist in the optimal management of urothelial cancer in the community setting. This initiative will review the mechanism of action for immunotherapies and emerging targeted therapies, summarize recent clinical data for these therapies, and examine best practices for the management of advanced and metastatic urothelial carcinoma. This initiative aims to provide guidance to the multidisciplinary cancer care team on the practical issues and barriers associated with new and emerging therapies in the community setting and strategies to engage patients in the shared decision-making process.

### **Learning Objectives**

At the end of this educational initiative, for patients with locally advanced or metastatic urothelial carcinoma, participants should be able to:

- Review available evidence for the use of checkpoint inhibitors and novel agents, including antibody drug conjugates and fibroblast growth factor receptor (FGFR) inhibitors
- Explore strategies for identification and management of immune-related and FGFR inhibitor-associated adverse events
- Discuss approaches to communicate safety and efficacy data to facilitate shared clinical decision making
- Outline effective solutions for improving coordination and communication within the multidisciplinary cancer care team to improve patient outcomes

### **Webinar Agenda**

Welcome and Introductions.....15 mins

Pre-Activity Assessment of Practice Patterns.....45 mins

Faculty will pose several questions to learn more about the challenges encountered

- Case discussions.....1 hour

- Discussion points within the clinical cases:
  - Available evidence for checkpoint inhibitors, newly approved FGFR inhibitor, and antibody drug conjugates
  - Clinical challenges in individualizing and optimizing treatment selection and sequencing
  - Adverse event assessment and management
- Care Coordination within the multidisciplinary care team.....30 mins
- Administrative challenges in management of urothelial carcinoma...45 mins
- Develop Action Plan.....30 mins
- Program Evaluation, Post-Activity Assessment, and Q&A.....15 mins

**Your Faculty:**

**Pedro Barata, MD, MSc**

Assistant Professor, Deming Department of Medicine,  
 Division of Hematology/Oncology, Genitourinary Cancers  
 Tulane University

**Erik Castle, MD**

Professor of Urology  
 Tulane University School of Medicine

**Kimberly Allman, MSN, CNP**

Certified Nurse Practitioner  
 Genitourinary Oncology  
 Cleveland Clinic  
 Cleveland, OH

**ACCREDITED CONTINUING EDUCATION**

**Accreditation Statement**



JOINTLY ACCREDITED PROVIDER\*  
 INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Association of Community Cancer Centers (ACCC). AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



**IPCE CREDIT™**

This activity was planned by and for the healthcare team, and learners will receive 4.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

**Credit Designation for Physicians**

AXIS Medical Education designates this live activity for a maximum of 4.0 *AMA PRA Category 1 Credit(s)™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Maintenance of Certification:** Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4 MOC point(s) in the American Board of Internal Medicine's (ABIM)

Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

### Credit Designation for Nursing

AXIS Medical Education designates this continuing nursing education activity for 4.0 contact hours.

*Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.*

### AXIS Contact Information

For information about the accreditation of this program please contact AXIS at [info@axismeded.org](mailto:info@axismeded.org).

### Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The **faculty** reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

<b>Name of Faculty or Presenter/Planner</b>	<b>Reported Financial Relationship</b>
Pedro Barata, MD, MSc.	<i>Consultant/Advisor:</i> Astellas, Bayer, Bristol-Myers Squibb, Caris, Clovis, Dendreon, Eisai, EMD Serono, and Janssen. <i>Contracted Research:</i> AstraZeneca and BlueEarth Diagnostics.
Erik Castle, MD	Nothing to disclose
Kimberly Allman, MSN, CNP	<i>Advisory Board:</i> Bayer. <i>Speakers Bureau:</i> Amgen and Exelixis.

The **Steering Committee** reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

<b>Steering Committee</b>	<b>Reported Financial Relationship</b>
Pedro Barata, MD, MSc.	<i>Consultant/Advisor:</i> Astellas, Bayer, Bristol-Myers Squibb, Caris, Clovis, Dendreon, Eisai, EMD Serono, and Janssen. <i>Contracted Research:</i> AstraZeneca and BlueEarth Diagnostics.
Kirollos S. Hanna, PharmD, BCPS, BCOP	<i>Consultant;</i> Abbvie, BeiGene, and Seattle Genetics. <i>Speakers Bureau:</i> Astellas, Abbvie, BeiGene, Bristol-Myers Squibb, Exelixis, and Seattle Genetics
Kimberly Allman, MSN, CNP	<i>Advisory Board:</i> Bayer. <i>Speakers Bureau:</i> Amgen and Exelixis.

The **planners, managers, and reviewers** reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

<b>Name of Planner/Manager/Reviewer</b>	<b>Reported Financial Relationship</b>
Latha Shivakumar, PhD	Nothing to disclose
Mary Stanley, PMP	Nothing to disclose
Leigh M. Boehmer, PharmD, BCOP	Nothing to disclose
Linda Gracie-King	Nothing to disclose
Marilyn Haas, PhD, RN, CNS, ANP-BC	Nothing to disclose
Dee Morgillo, MEd.,CHCP	Nothing to disclose
Robert Mocharnuk MD	Common stock: Merck

#### **Disclaimer**

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

#### **Disclosure of Unlabeled Use**

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

#### **Request for Credit:**

- Attend/participate in the educational activity and review all course materials.
- Complete the CE Attestation/Evaluation form online by 11:59 pm ET on **December 14, 2020. Instructions will be provided.**
- Upon successful completion of the online form, your statement of completion will be presented to you to print.